Welcome to the Winter issue of the newsletter!
You will be pleased to know we have once again been very busy in the last few months and here are some of the is-sues we have been handling.
As always the introduction of new treatments is never an easy job given all the financial constraints on health budgets nationwide and this time around is no exception.
CLLSA are extremely pleased by the NICE decision to approve Ibrutinib to treat NHS England and Wales chronic lymphocytic leukaemia patients.
Today’s Final Appraisal Determination (FAD) recommends that:
1.1Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:
· who have had at least 1 prior therapy or
We have a new flyer - please feel free to distribute to anyone affected by CLL whether Patient, Family, Friend or Health Peofessional especially your GPs surgery. No one should be alone when they are diagnosed.
2016 is already proving to be another very busy year for us all at CLLSA.
We have been taking another look at how we are set up with the help of a consultancy which is run by one of our members who very generously has given us their help at no charge. Many thanks!
The CLLSA have produced a new flyer - feel free to pass this to anyone you know who is affected by CLL whether Patient, Family Friend or Health Professions especially your GPs surgery.
If you are a health professional or member and would like a supply of our new leaflet to leave at your clinic/surgery please email our coordinator at firstname.lastname@example.org and they will be happy to post you some.
CLLSA is pleased to share that the Accelerated Access Review final report has now been published; it has been long awaited.
This anonymous patient survey lead by Leukaemia CARE is to aid understanding of the challenges of people affected by a blood cancer and help us to provide the patient voice to improve access to appropriate treatments..
Have your say.